S

E

SAMALIN , E.

Last name: SAMALIN

First name: E.

2014 (v1)

Journal article

Metadata-only

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Samalin, E. Bouche, O. Thezenas, S.

BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy. METHODS: In Phase I, in a 3+3 dose escalation schedule, patients received...

Uploaded on: December 4, 2022
April 2019 (v1)

Journal article

Metadata-only

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)

Adenis, Antoine Bennouna, J. Etienne, P.L.

PURPOSE:The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC).PATIENTS AND METHODS:E-DIS is a discontinuation trial, aimed at estimating efficacy, quality of life and safety of chemotherapy continuation (CT-CONT) in patients with mESCC who are free from progression after a...

Uploaded on: December 4, 2022